Swint to lead Travis Body and Trailer

Stocks, U.S. yields fall on worries over U.S. policy

Stocks, U.S. yields fall on worries over U.S. policy

World equity markets and U.S. bond yields fell while gold rose on Thursday as investors favored safe-haven investments amid skepticism U.S. President Donald Trump, roiled in controversy, would achieve his economic agenda. Adding to investor concerns was news that a van had slammed into crowds in the Spanish city of Barcelona, killing 13 people, according to media reports, in an attack police were treating as a terrorism. The U.S. dollar clung to a tiny gain and U.S. Treasury yields fell on worries Trump will be unable to deliver on campaign promises such as tax reform, even as the White House knocked down speculation that Gary Cohn, director of the National Economic Council, would resign.


...Read the rest of this story

CSX’s Hunter Harrison bashes U.S. trade groups over rail complaints

CSX Corp Chief Executive Hunter Harrison hit back at dozens of trade groups that urged a federal probe of service disruptions at the No. 3 U.S. railroad, saying their complaints were "grossly exaggerated," according to a letter seen by Reuters on Thursday. The Rail Customer Coalition this week asked federal rail regulators to investigate CSX's "chronic service failures." It called on Congress to make it easier for shippers to file complaints and allow other railroads to use CSX track during disruptions. Harrison responded to the shippers group, defending what he called the "transformational changes" implemented since he took over as CEO in March to boost CSX' productivity and finances.


...Read the rest of this story

Mylan, U.S. finalize $465 million EpiPen settlement

Mylan, U.S. finalize $465 million EpiPen settlement

Mylan NV (MYL.O) has finalized a $465 million settlement with the U.S. Justice Department, resolving claims it overcharged the government for its EpiPen emergency allergy treatment, which became the center of a firestorm over price increases. The U.S. Attorney's Office in Massachusetts revealed the accord on Thursday, 10 months after Mylan said it reached a deal resolving claims it misclassified the EpiPen as a generic rather than a branded product to avoid paying rebates owed to Medicaid. "Taxpayers rightly expect companies like Mylan that receive payments from taxpayer-funded programs to scrupulously follow the rules," Acting U.S. Attorney William Weinreb said in a statement.


...Read the rest of this story